Key Takeaway: EURORDIS-Rare Diseases Europe is a nonprofit alliance comprising 869 organizations dedicated to rare diseases across 71 countries. The initiative aims to enhance the quality of life for the estimated 30 million individuals affected by rare diseases in Europe. This collaborative effort highlights the importance of patient advocacy and support in the healthcare landscape.
Price reaction · baseline $3.53 (2023-09-22T16:20:00.000Z) · hit during market hours · 22 other OVID headline(s) in the window, move may be shared
day 0 close · peak
+3.1%
Market Sentiment Analysis
POSITIVE FACTORS
EURORDIS represents a large network of patient organizations.
The alliance aims to improve the lives of those with rare diseases.
It encompasses a significant number of countries and patients.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+622%
120-day peak, hindsight
Typical move
2.4%
average across 3 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Full Press Release Details
EURORDIS-Rare Diseases Europe is a unique, nonprofit alliance of 869 rare disease patient organizations from 71 countries that work together to improve the lives of the 30 million people living with a rare disease in Europe.
Visit Site »
Frequently Asked Questions
What is EURORDIS?
EURORDIS is a nonprofit alliance of 869 organizations focused on rare diseases.
How many countries are involved in EURORDIS?
EURORDIS includes patient organizations from 71 countries.
How many people are affected by rare diseases in Europe?
Approximately 30 million people in Europe live with a rare disease.
What is the goal of EURORDIS?
EURORDIS aims to improve the lives of individuals affected by rare diseases.
Biotech snapshot
Cash runway
$166M liquidity · $5M/mo burn
~33 mo
Minimal dilution risk
Catalyst track record
+622%
best trade around OVID's most recent catalyst
Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for OVID.